Anzeige
❌
Mehr »
Sonntag, 22.11.2026 - Börsentäglich über 12.000 News
Zufall oder Strategie? Copper One zündet die nächste Stufe seiner Kupfer-Offensive!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
RP

WKN: A40EFY | ISIN: US7665597024 | Ticker: RI2
Frankfurt
20.11.26 | 15:48
36,830 Euro
-2,39 % -0,900
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
RIGEL PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
RIGEL PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
36,37036,73019:04
35,78037,29020.11.

Aktuelle News zur RIGEL PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiRigel Pharmaceuticals auf der Jefferies Global Healthcare Conference: Dynamischer VEPPANU-Start treibt Wachstum an3
06.11.Rigel outlines $290M-$295M 2026 revenue outlook as VEPPANU launch starts with $6.6M sales4
10.09.Rigel forciert Wachstum mit Markteinführung von Veppanu1
RIGEL PHARMACEUTICALS Aktie jetzt für 0€ handeln
04.09.EVP & Chief Financial Officer At Rigel Pharmaceuticals Exercises Options Worth $123K3
05.08.Rigel projects $285M-$295M 2026 total revenue while preparing mid-august VEPPANU launch15
05.08.Rigel Q2 2026 slides: VEPPANU launch to transform portfolio2
04.08.RIGEL PHARMACEUTICALS INC - S-8, Securities to be offered to employees in employee benefit plans3
04.08.RIGEL PHARMACEUTICALS INC - 8-K, Current Report2
04.08.RIGEL PHARMACEUTICALS INC - 10-Q, Quarterly Report2
04.08.Rigel Pharmaceuticals, Inc.: Rigel Reports Second Quarter 2026 Financial Results423Second quarter 2026 total revenues of $78.7 million, including net product sales of $67.0 million and contract revenues from collaborations of $11.7 million, and...
► Artikel lesen
01.07.RIGEL PHARMACEUTICALS INC - 8-K, Current Report3
01.07.Rigel CMO Lisa Rojkjaer Retires, Alison Hannah Appointed As New CMO4
01.07.Rigel appoints Alison L. Hannah as chief medical officer1
01.07.Rigel Pharmaceuticals, Inc.: Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer576Dr. Hannah has decades of oncology drug development experience and has served on Rigel's Board of Directors since 2021 She has resigned from Rigel's Board of...
► Artikel lesen
17.06.RIGEL PHARMACEUTICALS INC - 8-K, Current Report6
17.06.Rigel to roll out Veppanu in August; Arvinas, Pfizer snag $70M upfront on cleared deal33
04.06.Insider Move: Dean Schorno Exercises Options, Realizing $52K At Rigel Pharmaceuticals4
15.05.Weekly Buzz: Lilly Posts Positive Trial Data, Rigel Pharmaceuticals Licenses PROTAC Drug, Bristol Myers Squibb Strikes $15.2B Deal1.240NEW YORK CITY (dpa-AFX) - This week's biotech highlights Lilly's strong Phase 3b maintenance results for Zepbound and Foundaya, Rigel's global license for the first FDA-approved PROTAC therapy...
► Artikel lesen
12.05.Rigel Pharma Signs Licensing Agreement With Arvinas And Pfizer For Veppanu715NEW YORK CITY (dpa-AFX) - Rigel Pharmaceuticals, Inc. (RIGL) on Tuesday said it has entered into a global license agreement with Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE) to develop, manufacture...
► Artikel lesen
05.05.Rigel Pharmaceuticals, Inc.: Rigel Reports First Quarter 2026 Financial Results353First quarter 2026 total revenues of $58.8 million, including net product sales of $54.9 million and contract revenues from collaborations of $3.9 million Generated...
► Artikel lesen
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1